Valneva Covid vaccine trial to compare 'old-fashioned' technology with AstraZeneca jab


Senior members of the committee have suggested they could extend the advice to those in their thirties if the background of Covid stays low.

Similar potentially linked clots in people who have taken the Johnson & Johnson vaccine have led scientists to speculate that the adenoviral vector platform technology used by both bursts may be the causative factor.

Valneva uses inactivated vaccine technology, a format that has been used for the past 100 years to vaccinate billions of people against diseases such as seasonal flu, hepatitis A, polio, and rabies. It injects a version of the live virus that is too weak to cause disease but strong enough to stimulate an immune response.

The candidate jab is also given as an adjuvant, which means it contains an ingredient designed to produce a stronger immune response - a technique similar to the flu shots targeted at retirees in annual influenza vaccination campaigns.

The shock has now completed the first and second phase safety and immunogenicity studies, in which the doses were "well tolerated with no safety concerns". Recruiting for the final phase will begin this week. The scientists hope to have the results available for submission to the regulatory authority in the fall.

Valneva can deliver up to 250 million doses of vaccine to the UK and other countries if the shock is found to be safe and effective. Up to 100 million doses have been seized as part of the UK government's vaccine procurement.


continue reading https://dailytechnonewsllc.com/valneva-covid-vaccine-trial-to-compare-old-fashioned-technology-with-astrazeneca-jab/?feed_id=7174&_unique_id=61d9d5c7a9dd3

Commentaires

Posts les plus consultés de ce blog

Projections for the gambling industry for 2022

Tremendous scope for India-US cooperation in health technology and pharma, says expert

Global Home Sleep Screening Wearable Devices Market Insights Report, Forecast to 2027 – KSU